{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:17:43Z","timestamp":1790813863044,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Low-grade chronic inflammation may persist in spontaneous human immunodeficiency virus controllers (HICs), leading to non-AIDS-defining events (nADEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two hundred twenty-seven antiretroviral therapy (ART)\u2013naive HICs (known human immunodeficiency virus type 1 [HIV-1] infection \u22655 years and at least 5 consecutive viral loads [VLs] &amp;lt;400 HIV RNA copies\/mL) were compared with 328 patients who initiated ART \u22641 month after primary HIV infection diagnosis and had undetectable VL within 12 months following ART initiation for at least 5 years. Incidence rates of first nADEs were compared between HICs and ART-treated patients. Determinants of nADEs were assessed by using Cox regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All-cause nADEs incidence rates were 7.8 (95% confidence interval [CI], 5.9\u20139.6) and 5.2 (95% CI, 3.9\u20136.4) per 100 person-months among HICs and ART patients, respectively (incidence rate ratio [IRR], 1.5 [95% CI, 1.1\u20132.2]; adjusted IRR, 1.93 [95% CI, 1.16\u20133.20]). After adjustment for the cohort, demographic, and immunological characteristics, the only other factor associated with all-cause nADE occurrence was age \u226543 (vs &amp;lt;43) years at the beginning of viral control (IRR, 1.69 [95% CI, 1.11\u20132.56]). The most frequent events observed in the 2 cohorts were non-AIDS-related benign infections (54.6% and 32.9% of all nADEs, respectively, for HICs and ART patients). No differences in cardiovascular or psychiatric events were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HICs experienced 2 times more nADEs than virologically suppressed patients on ART, mainly non-AIDS-related benign infections. Older age was associated with nADE occurrence, independent of immune or virologic parameters. These results do not argue in favor of expanding the ART indication for HICs but rather a case-by-case approach considering clinical outcomes such as nADEs besides immune activation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofad067","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T08:11:47Z","timestamp":1675843907000},"source":"Crossref","is-referenced-by-count":5,"title":["Non-AIDS-Defining Events in Human Immunodeficiency Virus Controllers Versus Antiretroviral Therapy\u2013Controlled Patients: A Cohort Collaboration From the French National Agency for Research on AIDS CO21 (CODEX) and CO06 (PRIMO) Cohorts"],"prefix":"10.1093","volume":"10","author":[{"given":"Carmelite","family":"Manto","sequence":"first","affiliation":[{"name":"INSERM U1018, Universit\u00e9 Paris Saclay, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations (CESP) , Le Kremlin Bic\u00eatre , France"},{"name":"Clinical Research Education, Networking & Consultancy (CRENC) , Douala , Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Castro-Gordon","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris.Universit\u00e9 Paris-Saclay, Service de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Goujard","sequence":"additional","affiliation":[{"name":"INSERM U1018, Universit\u00e9 Paris Saclay, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations (CESP) , Le Kremlin Bic\u00eatre , France"},{"name":"Assistance Publique-H\u00f4pitaux de Paris.Universit\u00e9 Paris-Saclay, Service de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Meyer","sequence":"additional","affiliation":[{"name":"INSERM U1018, Universit\u00e9 Paris Saclay, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations (CESP) , Le Kremlin Bic\u00eatre , France"},{"name":"Assistance Publique-H\u00f4pitaux de Paris.Universit\u00e9 Paris-Saclay, Service de Sant\u00e9 Publique, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris.Universit\u00e9 Paris-Saclay, Service de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre , France"},{"name":"Unit\u00e9 mixte de recherche (UMR) INSERM\/CEA\/Universit\u00e9 Paris Saclay U1184, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes (ImVA) , Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Essat","sequence":"additional","affiliation":[{"name":"INSERM U1018, Universit\u00e9 Paris Saclay, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations (CESP) , Le Kremlin Bic\u00eatre , France"},{"name":"Assistance Publique-H\u00f4pitaux de Paris.Universit\u00e9 Paris-Saclay, Service de Sant\u00e9 Publique, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoo","family":"Shaiykova","sequence":"additional","affiliation":[{"name":"INSERM U1018, Universit\u00e9 Paris Saclay, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations (CESP) , Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faroudy","family":"Boufassa","sequence":"additional","affiliation":[{"name":"INSERM U1018, Universit\u00e9 Paris Saclay, Centre de recherche en Epid\u00e9miologie et Sant\u00e9 des Populations (CESP) , Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"No\u00ebl","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris.Universit\u00e9 Paris-Saclay, Service de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Bic\u00eatre , Le Kremlin-Bic\u00eatre , France"},{"name":"Unit\u00e9 mixte de recherche (UMR) INSERM\/CEA\/Universit\u00e9 Paris Saclay U1184, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes (ImVA) , Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e3181f7f61a","article-title":"Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection","volume":"56","author":"Baker","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/cid\/ciw683","article-title":"Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection","volume":"64","author":"Sereti","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"INSIGHT START Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"Mussini","year":"2015","journal-title":"Lancet HIV"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/infdis\/jit025","article-title":"Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14","volume":"207","author":"M\u00e9ndez-Lagares","year":"2013","journal-title":"J Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"103129","DOI":"10.1016\/j.ebiom.2020.103129","article-title":"Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection","volume":"62","author":"Novelli","year":"2020","journal-title":"EBioMedicine"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001554","article-title":"Inflammation-related morbidity and mortality among HIV-positive adults: how extensive is it?","volume":"77","author":"Hart","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e000844","DOI":"10.1161\/JAHA.114.000844","article-title":"Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation","volume":"3","author":"Nordell","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/QAD.0b013e32835f6b0c","article-title":"Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers","volume":"27","author":"Borges","year":"2013","journal-title":"AIDS"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.it.2007.09.002","article-title":"ANRS EP36 HIV CONTROLLERS study group. HIV controllers: how do they tame the virus?","volume":"28","author":"S\u00e1ez-Ciri\u00f3n","year":"2007","journal-title":"Trends Immunol"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy","volume":"27","author":"Deeks","year":"2007","journal-title":"Immunity"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e86719","DOI":"10.1371\/journal.pone.0086719","article-title":"An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration","volume":"9","author":"Olson","year":"2014","journal-title":"PLoS One"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/QAD.0000000000000049","article-title":"A systematic review of definitions of extreme phenotypes of HIV control and progression","volume":"28","author":"Gurdasani","year":"2014","journal-title":"AIDS"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"ofx064","DOI":"10.1093\/ofid\/ofx064","article-title":"A subset of extreme human immunodeficiency virus (HIV) controllers is characterized by a small HIV blood reservoir and a weak T-cell activation level","volume":"4","author":"Canou\u00ef","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/QAD.0000000000000174","article-title":"Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients","volume":"28","author":"Noel","year":"2014","journal-title":"AIDS"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e15924","DOI":"10.1371\/journal.pone.0015924","article-title":"A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers","volume":"6","author":"Hunt","year":"2011","journal-title":"PLoS One"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/jit581","article-title":"Evidence for innate immune system activation in HIV type 1-infected elite controllers","volume":"209","author":"Krishnan","year":"2014","journal-title":"J Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e1003691","DOI":"10.1371\/journal.ppat.1003691","article-title":"Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers","volume":"9","author":"Hatano","year":"2013","journal-title":"PLoS Pathog"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e85516","DOI":"10.1371\/journal.pone.0085516","article-title":"Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration","volume":"9","author":"Boufassa","year":"2014","journal-title":"PLoS One"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/cid\/ciz442","article-title":"Antiretroviral therapy reduces T-cell activation and immune exhaustion markers in human immunodeficiency virus controllers","volume":"70","author":"Li","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3018(19)30264-4","article-title":"HIV controllers: to treat or not to treat? Is that the right question?","volume":"6","author":"No\u00ebl","year":"2019","journal-title":"Lancet HIV"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/infdis\/jiu809","article-title":"Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection","volume":"211","author":"Crowell","year":"2015","journal-title":"J Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"20524","DOI":"10.7448\/IAS.19.1.20524","article-title":"Hospitalizations among HIV controllers and persons with medically controlled HIV in the U. S. military HIV natural history study","volume":"19","author":"Crowell","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1089\/aid.2012.0367","article-title":"Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells\/mm3","volume":"29","author":"Lucero","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/ciw120","article-title":"Analysis of non-AIDS-defining events in HIV controllers","volume":"62","author":"Dominguez-Molina","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/cid\/cix1068","article-title":"Long-term therapeutic impact of the timing of antiretroviral therapy in patients diagnosed with primary human immunodeficiency virus type 1 infection","volume":"66","author":"Novelli","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e0184329","DOI":"10.1371\/journal.pone.0184329","article-title":"Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach","volume":"12","author":"Masi\u00e1","year":"2017","journal-title":"PLoS One"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/cid\/cix343","article-title":"Hospitalization rates among people with HIV\/AIDS in New York City, 2013","volume":"65","author":"Lazar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e0131922","DOI":"10.1371\/journal.pone.0131922","article-title":"Immunologic and virologic progression in HIV controllers: the role of viral \u2018blips' and immune activation in the ANRS CO21 CODEX study","volume":"10","author":"Noel","year":"2015","journal-title":"PLoS One"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/01.aids.0000431945.72365.01","article-title":"Natural history of HIV-control since seroconversion","volume":"27","author":"Madec","year":"2013","journal-title":"AIDS"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/QAD.0b013e32832b514b","article-title":"Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis","volume":"23","author":"Hsue","year":"2009","journal-title":"AIDS"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/QAD.0b013e32835a9950","article-title":"Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers","volume":"26","author":"Pereyra","year":"2012","journal-title":"AIDS"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1097\/QAI.0000000000002108","article-title":"Cardiovascular events in the French ANRS HIV controller cohort","volume":"82","author":"No\u00ebl","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ajh\/hpz132","article-title":"Role of inflammatory biomarkers in the prevalence and incidence of hypertension among HIV-positive participants in the START trial","volume":"33","author":"Ghazi","year":"2020","journal-title":"Am J Hypertens"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3389\/fimmu.2019.01378","article-title":"How monocytes contribute to increased risk of atherosclerosis in virologically-suppressed HIV-positive individuals receiving combination antiretroviral therapy","volume":"10","author":"Jaworowski","year":"2019","journal-title":"Front Immunol"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/JVI.02098-13","article-title":"Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers","volume":"88","author":"L\u00e9curoux","year":"2014","journal-title":"J Virol"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3018(18)30295-9","article-title":"Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies","volume":"6","author":"Althoff","year":"2019","journal-title":"Lancet HIV"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"e46143","DOI":"10.1371\/journal.pone.0046143","article-title":"Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection","volume":"7","author":"Liovat","year":"2012","journal-title":"PLoS One"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.eclinm.2021.100963","article-title":"Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort","volume":"37","author":"Pla\u00e7ais","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2023022215451742800_","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0000000000002052","article-title":"ART in HIV-positive persons with low pretreatment viremia: results from the START trial","volume":"81","author":"Sereti","year":"2019","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad067\/49121547\/ofad067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/2\/ofad067\/49297488\/ofad067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/2\/ofad067\/49297488\/ofad067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T12:59:48Z","timestamp":1679662788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad067\/7031070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad067","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2023,2,1]]},"article-number":"ofad067"}}